AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
Managing Enfortumab Vedotin-Induced Peripheral Neuropathy: A Practical Case Review
By Alexandra Koehler, DNP
Enfortumab vedotin plus pembrolizumab (EV+P) has transformed frontline treatment for metastatic urothelial carcinoma, roughly doubling median overall survival compared with platinum-based chemotherapy in the EV-302 trial.
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
RASolute 302: A Turning Point for RAS-Targeted Therapy in Pancreatic Cancer
By Brandon G. Smaglo, MD
The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years:
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case
By Erica Doubleday, NP
Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.